Online citations, reference lists, and bibliographies.

Biodegradable Intranasal Nanoparticulate Drug Delivery System Of Risedronate Sodium For Osteoporosis

M. Fazil, M. Q. Hassan, S. Baboota, J. Ali
Published 2016 · Medicine, Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Context: Osteoporosis (OP) is the most common metabolic bone disease predominantly found in elderly people. It is associated with reduced bone mineral density, results in a higher probability of fractures, especially of the hip, vertebrae, and distal radius. Worldwide prevalence of OP is considered a serious public health concern. Objective: The purpose of the present work was to develop and evaluate polymeric nanoparticles (NPs) of risedronate sodium (RIS) for the treatment of OP using intranasal (IN) route in order to reduce peripheral toxic effects. Materials and methods: Polymeric NPs of RIS were prepared by nanoprecipitation methods. Formulations were developed and evaluated in context to in vitro drug release, ex vivo permeation, in vivo study, and biochemical studies. Results and discussions: The particles size, entrapment efficiency (EE) (%), and loading capacity (LC) (%) of optimized formulations were found to be 127.84 ± 6.33 nm, 52.65 ± 5.21, and 10.57 ± 1.48, respectively. Release kinetics showed diffusion-controlled, Fickian release pattern. Ex vivo permeation study showed RIS from PLGA-NPs permeated significantly (p < 0.05) through nasal mucosa. In vivo study showed a marked difference in micro-structure (trabeculae) in bone internal environment. Biochemical estimation of treated group and RIS PLGA indicated a significant recovery (p < 0.01) as compared with the toxic group. Conclusion: Polymeric NPs of RIS were prepared successfully using biodegradable polymer (PLGA). Intranasal delivery showed a good result in in vivo study. Thus PLGA-NPs have great potential for delivering the RIS for the treatment and prevention of OP after clinical evaluation in near future.
This paper references
10.1211/0022357022539
Is nose-to-brain transport of drugs in man a reality?
L. Illum (2004)
10.1016/J.SEMARTHRIT.2006.12.003
Recent developments in bisphosphonate therapy.
S. Silverman (2007)
10.1016/j.ejps.2012.04.013
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
M. Fazil (2012)
10.1016/0168-3659(87)90035-6
A simple equation for description of solute release II. Fickian and anomalous release from swellable devices
P. L. Ritger (1987)
10.1002/JPS.10143
Preparation, characterization, and drug release behaviors of drug nimodipine‐loaded poly(ε‐caprolactone)‐poly(ethylene oxide)‐poly(ε‐caprolactone) amphiphilic triblock copolymer micelles
Haixiong Ge (2002)
10.1016/S0939-6411(97)00056-8
Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres
M. D. Blanco (1997)
10.1016/J.ACA.2006.11.012
Development and validation of a reversed-phase ion-pair high-performance liquid chromatographic method for the determination of risedronate in pharmaceutical preparations.
D. Kyriakides (2007)
10.3109/10717544.2014.900153
Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis
Deepa Saini (2015)
10.1016/S0169-409X(01)00245-9
Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells.
S. Vinogradov (2002)
10.1016/S0168-3659(98)00116-3
PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug.
T. Govender (1999)
10.1016/j.bone.2011.10.017
Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model.
So Hee Nam (2012)
Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 1-14
S Deepa (2014)
10.1186/1471-2474-8-12
Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis
C. Hurson (2007)
10.1002/art.23954
Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.
W. Yao (2008)
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats.
D. Banji (2014)
10.1016/J.EJPB.2004.03.010
In vitro permeation studies comparing bovine nasal mucosa, porcine cornea and artificial membrane: androstenedione in microemulsions and their components.
Telse Richter (2004)
10.1590/S0042-96862003000900008
New approaches to pharmacological treatment of osteoporosis.
K. Akesson (2003)
10.1016/S0168-3659(96)01484-8
Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery
Cunxian Song (1997)
10.1016/j.rinphs.2011.06.001
Comparative evaluation of humic substances in oral drug delivery.
Mohd. Aamir Mirza (2011)
10.4314/TJPR.V5I1.14634
Nanoparticles - A Review
V. Mohanraj (2007)
10.1016/j.actbio.2011.07.025
Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.
U. Seju (2011)
10.1016/8756-3282(95)00445-9
Bisphosphonates: a review of their pharmacokinetic properties.
J. Lin (1996)
10.1016/j.ejps.2009.04.004
Quantifying drug release from PLGA nanoparticulates.
O. I. Corrigan (2009)
10.1016/j.ejpb.2011.07.010
Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.
Maha Nasr (2011)
10.1016/S0142-9612(00)00040-5
Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles.
M. Dunne (2000)
10.1023/A:1011024200280
Risedronate Pharmacokinetics and Intra- and Inter-Subject Variability Upon Single-Dose Intravenous and Oral Administration
D. Y. Mitchell (2004)
10.3390/POLYM3031377
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.
Hirenkumar K. Makadia (2011)
10.1111/j.1572-0241.2000.03258.x
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae
F. Lanza (2000)
10.1016/j.ejpb.2010.07.007
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Shrinidh A Joshi (2010)
10.4103/0019-5413.73656
Epidemiology of hip fracture: Worldwide geographic variation
D. Dhanwal (2011)
10.1681/ASN.2008010014
Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.
D. Regidor (2008)
10.1007/s11095-010-0152-4
In Vitro–In Vivo Correlations of Scalable PLGA-Risperidone Implants for the Treatment of Schizophrenia
L. Amann (2010)
Influence of particle size and dissolution condition on the degradation properties of polylactideco-glycolide particles
M Dunne (2000)
NPs – a review
VJ Mohanraj (2006)
10.1093/RHEUMATOLOGY/39.5.523
Acute effects of etidronate on glucocorticoid-induced bone degradation.
A. Struijs (2000)
10.1177/36.1.3275709
A new decalcifying technique for immunohistochemical studies of calcified tissue, especially applicable to cell surface marker demonstration.
S. Mori (1988)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1097/BOR.0b013e3282f51031
The epidemiology of glucocorticoid-associated adverse events
Allyson K McDonough (2008)
10.1111/J.1365-2710.2004.00597.X
Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
W. Li (2004)
10.1016/J.IJPHARM.2006.11.061
Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
A. Budhian (2007)
10.1080/10611860903046628
Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, an in vitro cell line and in vivo biodistribution studies on rat model
N. Shah (2009)



This paper is referenced by
10.1080/02652048.2019.1631401
Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies
Santhosh S (2019)
10.1080/03639045.2019.1572184
Bioactive injectable triple acting thermosensitive hydrogel enriched with nano-hydroxyapatite for bone regeneration: in-vitro characterization, Saos-2 cell line cell viability and osteogenic markers evaluation
Nadia M. Morsi (2019)
II Dedication To My : Father ’ s Soul , Mother , Brothers and Sisters
Mazen F. Abu Qamar (2017)
10.1080/09205063.2017.1354675
Construction of a PLGA based, targeted siRNA delivery system for treatment of osteoporosis
Deniz Sezlev Bilecen (2017)
10.18632/oncotarget.7519
A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo
W. Wang (2016)
10.1016/B978-0-08-100262-9.00017-3
Applications of bioresorbable polymers in the skeletal systems (cartilages, tendons, bones)
E. C. Ekwueme (2017)
10.1208/s12249-019-1561-2
QbD Approach for Novel Crosslinker-Free Ionotropic Gelation of Risedronate Sodium–Chitosan Nebulizable Microspheres: Optimization and Characterization
Omar A. Elkady (2019)
10.1016/j.ijpharm.2018.03.053
Star‐shaped poly(oligoethylene glycol) copolymer‐based gels: Thermo‐responsive behaviour and bioapplicability for risedronate intranasal delivery
M. Soliman (2018)
The Association between Desalinated Drinking Water and Osteoporosis in Patients from 20-50 Years ’ Old in Gaza Strip
A. Qamar (2017)
Semantic Scholar Logo Some data provided by SemanticScholar